Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 7, 2025
Global Pet Dietary Supplements Market Surges Amid Innovation and Rising Pet Wellness Trends
GlobeNewswire
·
May 7, 2025
Delray Beach, FL, May 07, 2025 (GLOBE NEWSWIRE) -- The global pet dietary supplements market is experiencing dynamic growth, fueled by increased pet ownership, product innovation, and a heightened focus on animal wellness. As pet parents seek more …
e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
GlobeNewswire
·
May 7, 2025
LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present new preclinical results on its GalOmic small‑ …
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
GlobeNewswire
·
May 7, 2025
BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1- …
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
GlobeNewswire
·
May 7, 2025
Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier …
Pramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline
GlobeNewswire
·
May 7, 2025
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Pramana Pharmaceuticals, a late-stage preclinical biopharmaceutical company developing a transformative small molecule platform targeting the intersection of metabolism, immunity, and …
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast
GlobeNewswire
·
May 7, 2025
HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced …
Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
GlobeNewswire
·
May 7, 2025
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced additional data from its Phase 2 clinical study ( …
Ultrack Systems Inc. (OTC: MJLB) Announces Better Pets U.S. Trademark Class Application for Full-Spectrum Pet Wellness Product Line
GlobeNewswire
·
May 7, 2025
CONCORD, Ontario, May 07, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB), an emerging diversified holding company, is pleased to announce that Better Pets, its recent strategic acquisition target under a signed Memorandum of Understanding (MOU), …
Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
GlobeNewswire
·
May 7, 2025
ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, …
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
GlobeNewswire
·
May 7, 2025
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 …
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
GlobeNewswire
·
May 7, 2025
MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and …
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
GlobeNewswire
·
May 7, 2025
Secured ten new fully-issued patents related to hypertension treatment during last 12 months, bringing global issued patent estate total for this condition to 120 patents Patent estate covering atrioventricular interval modulation (“AVIM”) therapy now …
PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement
GlobeNewswire
·
May 7, 2025
- Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE …
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
GlobeNewswire
·
May 7, 2025
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative …
STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update
GlobeNewswire
·
May 7, 2025
HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic …
Avance Clinical Sponsors Prestigious Citeline Awards 2025 To Recognize Innovative Biotechnology Companies
GlobeNewswire
·
May 7, 2025
ADELAIDE, Australia and BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning, global CRO for biotechs, is proud to announce its sponsorship of the Citeline Awards 2025, to be held in Boston tomorrow, May 8, 2025. Recognized as a …
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
GlobeNewswire
·
May 7, 2025
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today …
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an …
Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference
GlobeNewswire
·
May 7, 2025
SYDNEY, May 07, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet …
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
GlobeNewswire
·
May 7, 2025
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity …